Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of Utah, Salt Lake City.
Comparative Effectiveness, Cost and Outcomes Research Center, University of Washington, Seattle.
JAMA Otolaryngol Head Neck Surg. 2020 Mar 1;146(3):270-277. doi: 10.1001/jamaoto.2019.4469.
With the increasing emphasis on economic evaluations, there is a need for additional methods of measuring patient utility in the obstructive sleep apnea population.
To develop and validate a utility scoring algorithm for a sleep apnea-specific quality-of-life instrument.
DESIGN, SETTING, AND PARTICIPANTS: Development and validation were conducted at 2 tertiary referral sleep centers and associated sleep clinics and included patients with newly diagnosed obstructive sleep apnea from a randomized clinical trial and an associated observational cohort study. Baseline participants were randomly divided into a model development group (60%) and a cross-validation group (40%).
Utility scoring of the Symptoms of Nocturnal Obstruction and Related Events (SNORE-25) was mapped from the SF-6D utility index through multiple linear regression in the development sample using the Akaike information criterion to determine the best model.
A total of 500 participants (development, n = 300; validation, n = 200) were enrolled; the analyzed sample of 500 participants included 295 men (59%), and the mean (SD) age was 48.6 (12.8) years, with a range of 18 to 90 years. The mean (SD) SF-6D utility among participants with untreated sleep apnea was 0.61 (0.08; range, 0.40-0.85) with similar utility across sleep apnea severity groups. The best-fit model (the SNORE Utility Index) was the natural log conversion of the instrument subscales (r2 = 0.32 in the development sample). The SNORE Utility Index retained this association within the validation sample (r2 = 0.33).
The SNORE Utility Index provides a validated, disease-specific, preference-weighted utility instrument that can be used in future studies of patients with obstructive sleep apnea.
随着对经济评估的重视日益增加,需要在阻塞性睡眠呼吸暂停人群中采用其他方法来衡量患者的效用。
开发和验证一种用于睡眠呼吸暂停特定生活质量量表的效用评分算法。
设计、地点和参与者:在 2 个三级转诊睡眠中心和相关睡眠诊所进行了开发和验证,纳入了来自随机临床试验和相关观察队列研究的新诊断为阻塞性睡眠呼吸暂停的患者。基线参与者被随机分为模型开发组(60%)和交叉验证组(40%)。
通过在开发样本中使用赤池信息量准则(Akaike information criterion)进行的多项线性回归,将症状性夜间呼吸阻塞和相关事件(Symptoms of Nocturnal Obstruction and Related Events,SNORE-25)的评分映射到 SF-6D 效用指数,以确定最佳模型。
共纳入 500 名参与者(开发组,n=300;验证组,n=200);在 500 名分析参与者中,295 名为男性(59%),平均(SD)年龄为 48.6(12.8)岁,范围为 18 至 90 岁。未经治疗的睡眠呼吸暂停患者的平均(SD)SF-6D 效用为 0.61(0.08;范围为 0.40-0.85),不同严重程度的睡眠呼吸暂停组之间的效用相似。最佳拟合模型(SNORE 效用指数)为仪器子量表的自然对数转换(开发样本中的 r2=0.32)。SNORE 效用指数在验证样本中保留了这种关联(r2=0.33)。
SNORE 效用指数提供了一种经过验证的、特定于疾病的、偏好加权的效用工具,可用于未来阻塞性睡眠呼吸暂停患者的研究。